Sublicensing. Coya shall have the right to grant and authorize sublicenses under the rights granted to it under Section 2.2 (Licenses to Coya) to any of its Affiliates and Third Parties through multiple tiers (each such Third Party, a “Sublicensee”); provided that each sublicense will be subject to a written agreement consistent with the terms and conditions of this Agreement. In no event will any sublicense relieve Coya of any obligations under this Agreement. Coya will promptly provide ARScience Bio copies of all Sublicense agreements, other than any vendor agreements or other agreements pursuant to which a Third Party is acting on behalf of Coya, which shall be kept confidentially by ARScience Bio in accordance with the confidentiality provisions herein and subject to Coya’s right to redact terms that are competitively sensitive and do not relate to any rights or obligations that would be applicable to ARScience Bio as licensor.

Sublicensing. For clarity, the license granted by FibroGen Cayman to AstraZeneca in Section 7.1 may be sublicensed by AstraZeneca to: # an Affiliate of AstraZeneca without any requirement of consent, provided that such sublicense to an Affiliate of AstraZeneca shall immediately terminate if and when such party ceases to be an Affiliate of AstraZeneca or # a Third Party only with the prior written consent of FibroGen Cayman, except where such sublicensing is permitted under an applicable Development Plan or Commercialization Plan, in which case consent shall not be required.

Sublicensing. In the event that Janssen grants any sublicense of the license rights granted to Janssen under this [Section 2.1] to any Affiliates or any Third Parties, Janssen shall remain responsible for its obligations under this Agreement and shall be responsible for the performance of the relevant sublicensee and the compliance by such sublicensee with the terms and conditions of this Agreement. Any sublicense granted by Janssen under this [Section 2.1] to any Third Party not working under Janssen’s or its Affiliates’ control and direction shall refer to this Agreement and shall not conflict with Janssen’s obligations under this Agreement, and Janssen will, within a reasonable time period after granting such sublicense, provide a copy of the sublicensing agreement to Arrowhead, which agreement may be redacted to omit any terms not relevant to determining Janssen’s and the Third Party sublicensee’s obligations under this Agreement.

Sublicensing. BMS shall have the right to grant sublicenses, through multiple tiers of sublicenses, under the licenses granted in [Section 5.1.1] to Affiliates and Sublicensees; provided that any such sublicenses to Sublicensees shall be in writing and shall be consistent with the terms and conditions of this Agreement. In addition, BMS shall require the applicable Affiliate and Sublicensee to comply with the terms of this Agreement that are applicable to such sublicense, including obligations of confidentiality and non-use at least as stringent as those set forth in ARTICLE 12, the reporting, record keeping and audit requirements set forth under ARTICLE 7, and the ETB Platform-related license grant back provisions set forth in [Section 5.2.2]. ​. BMS shall remain directly liable to MTEM with respect to its obligations under this Agreement and for the performance and acts or omissions of all of its Affiliates and Sublicensees. As soon as practicable, but in any event within ​, after the execution of any sublicense agreement with a Sublicensee hereunder, BMS shall notify MTEM that it has entered into such sublicense agreement, identifying the name of the Sublicensee and the scope of such sublicense. ​.

Sublicensing. Company shall not sell, sublicense, or otherwise transfer any right of Company under this Agreement to any third party (except as provided in [Section 2.6]), and any attempt at such a sublicense,

Sublicensing. To the extent that the licenses granted under [Sections 2.1 and 2.2]2] are sublicensable, the sublicensing Party shall comply with the following obligations:

Sublicensing. MEDINET shall have the right to grant sublicenses, through multiple tiers, under the licenses and sublicenses granted to MEDINET under [Section 2.01(a)], to its Affiliates without the prior consent of, but with written notice to, Histogenics. MEDINET shall have the right to grant sublicenses, through multiple tiers, under the licenses and sublicenses granted to MEDINET under [Section 2.01(a)], to Third Parties only with the prior written consent of Histogenics, which consent shall not be unreasonably withheld. For clarity, reasonable bases for Histogenics to withhold consent for such a sublicense may include but not be limited to # not wanting a sublicense to be granted to one of Histogenics’ competitors, or # reasonable questions about a potential Sublicensee’s ethics, reputation or track record of compliance with Applicable Laws. MEDINET shall ensure that all Sublicensees comply with all terms and conditions of this Agreement. MEDINET shall remain liable for any action or failure to act by any Sublicensee that would constitute a breach of this Agreement if such action or failure were committed by MEDINET.

Sublicensing. Each sublicense of the license granted in Section 2.1 must be pursuant to a written agreement that is consistent with the terms and conditions of this Agreement and is explicitly made subject and subordinate to this Agreement. Company shall provide Licensor with a copy of each sublicense agreement within thirty (30) days after the grant of such sublicense, which copy may be redacted by Company, provided that such redacted copy shall enable Licensor to verify that such sublicense complies with this Agreement. Company shall remain responsible for each sublicensee’s compliance with this Agreement. Licensor acknowledges and agrees that the existence of any such sublicense and the content of each sublicense is Company’s Confidential Information.

Sublicensing. The license granted by Janssen to Fate under this Section 3.1 shall be sublicensable only to the extent provided in Section 3.2.

Subject to Section 3.3(b), each Party shall have the right to grant sublicenses under the licenses granted to it under Section 3.1 to Affiliates and, if required for a Third Party to perform its duties with respect to the conduct of the Combined Therapy Trials (and agreed to by the other Party, such consent not to be unreasonably withheld), to Third Parties, solely as necessary to assist a Party in carrying out its responsibilities with respect to the Combined Therapy Trials.